Skip to the stories
Nutrition

Hyperarousal Is a Question, Not an Answer for Stubborn Insomnia

By David McCarty 550 views

Hyperarousal describes wired, fragmented sleep but doesn't explain it. Iron status, PAP-related breathing shifts and long-term sedative use are worth checking.

Hyperarousal Is a Question, Not an Answer for Stubborn Insomnia

Hyperarousal sounds like an explanation. It isn't. It's a description, and that gap matters for anyone dealing with sleep that won't cooperate. A patient who can't drift off because their nervous system is "hyperaroused" has received an accurate label and very little direction. The more useful next step is asking what's driving the arousal in the first place.

Sleep clinicians know the scene well. A person has been diagnosed with sleep apnea, uses CPAP faithfully, and the device data look good. Yet the sleep is still broken, the wake periods drag on, and bedtime feels like a fight. The machine has become a source of frustration rather than relief. Hyperarousal often enters the conversation right about here, when the diagnosis being treated seems to have stopped explaining the problem.

The term isn't wrong. It covers the physiological, cognitive and emotional sides of heightened activation, and it captures something the blunt word "insomnia" misses. The trouble starts when a description gets mistaken for a cause. Saying someone can't sleep because their nervous system is hyperaroused is roughly like saying they're awake because their brain isn't inclined to sleep. True enough, but it doesn't tell anyone what to check next.

A habit against stopping too early

David McCarty, a sleep medicine physician, has long warned about what he calls search satisficing: the tendency to stop investigating once one plausible explanation turns up. His "five-finger" framework prompts clinicians to consider circadian influences, medication effects, medical contributors, psychiatric and psychosocial factors, and primary sleep disorders. The goal isn't to produce five diagnoses for every patient. It's to remember that finding one real abnormality doesn't release you from looking at the other four domains.

That habit matters most when obstructive sleep apnea and insomnia occur together. The term COMISA, for comorbid insomnia and sleep apnea, describes a common combination accurately. It doesn't explain why a given patient stays awake. Cognitive behavioral therapy for insomnia, known as CBT-I, is an effective, evidence-based approach, and there are data suggesting it works for many people with coexisting sleep apnea. But McCarty's concern is that COMISA could become another stopping point, a neat label that discourages a closer look at competing physiological problems.

Three of those competing problems are common and under-recognized: altered sleep-regulatory signaling linked to iron deficiency, ventilatory instability produced or worsened by positive airway pressure therapy, and adaptive nervous system changes after long-term sedative use. Each shows a different route to persistent wakefulness. Each also has a different level of evidence behind it, which is worth keeping in view as we go.

Iron: the story reaches beyond restless legs

Iron deficiency usually enters sleep medicine through restless legs syndrome. Clinicians recognize the urge to move, the uncomfortable sensations that worsen at rest and ease with movement, and sometimes periodic limb movements on a sleep study. The link is strong enough that iron studies have become a routine part of a sleep evaluation whenever someone starts rubbing their thighs at bedtime.

But the legs are only part of the story. Iron participates in several processes relevant to central nervous system function, including dopamine signaling and the balance of excitatory and inhibitory neurotransmission. One line of investigation focuses on adenosine, a neuromodulator that builds up during waking hours and adds to the pressure to sleep. Caffeine feels alerting because it blocks adenosine receptors, temporarily muting that pressure signal.

Researchers led by Ferré have proposed that low iron in the brain may produce a hypoadenosinergic state, meaning reduced adenosine signaling along with shifts in glutamate and dopamine activity. In this model, less iron weakens an inhibitory brake on the systems that keep a person awake. It's a provocative idea, and it's still a proposal in an evolving field, not an established explanation for insomnia. Still, it offers a possible reason some people with restless legs seem to lose substantial sleep without the daytime sleepiness you'd expect. Their nervous systems may be responding to sleep loss differently.

There's a practical wrinkle here too. A normal hemoglobin doesn't rule out depleted iron stores, and serum ferritin, while useful, is an imperfect stand-in for iron status in the central nervous system. An older study of people with idiopathic restless legs found lower ferritin and higher transferrin in cerebrospinal fluid, even though the corresponding blood measures didn't show the same differences. The finding suggests that iron regulation in the brain can diverge from what a routine blood draw shows. That's a distinction worth remembering when a lab report comes back looking fine.

Pediatric research adds another angle. Some children have frequent, large body movements during sleep without meeting the standard criteria for restless legs syndrome. Early studies found low ferritin in many of these children, and later work produced consensus diagnostic criteria for what's now called restless sleep disorder. Researchers have also examined the cyclic alternating pattern, an EEG measure of how non-REM sleep is organized, and found altered sleep microstructure in these children. That supports the idea that iron deficiency may be part of a broader arousal picture rather than a simple leg problem.

None of this means iron deficiency causes every form of restless sleep, and none of it shows that iron supplementation will reliably calm the brain's sleep signals. A 2020 scoping review documented a substantial body of research linking iron deficiency with sleep disturbance, particularly restless legs. The case weakens considerably when it's extended to nonspecific insomnia, which is a reminder that other factors are usually in play. Current American Academy of Sleep Medicine guidance recommends iron studies in people with clinically significant restless legs syndrome, and it recognizes treatment thresholds that differ from those used to diagnose iron deficiency in general.

So what does this mean in a clinic? It doesn't mean every person with insomnia should be supplemented. It means that restless legs symptoms, periodic limb movements, a restless-sleep pattern in a child, or a history suggesting nutritional risk, such as childhood growth spurts, malabsorption or multiple dietary restrictions, should prompt a proper look at iron status. That look includes ferritin and transferrin saturation, interpreted in context. If iron treatment is considered, it should follow established indications and include monitoring. Please don't start iron on your own based on a sleep article, and do talk with your clinician before changing any supplement.

David E. McCarty, MD, FAASM
David E. McCarty, MD, FAASM

An ordinary blood count doesn't exclude a clinically relevant problem with iron physiology, and the effects of low iron may reach well beyond the movements you can see.

When breathing support overshoots

Positive airway pressure is designed to keep the upper airway open during sleep, and in most people it does that without destabilizing breathing control. In a susceptible minority, though, restoring airway patency can backfire. Central respiratory events, where the brain's breathing signal itself becomes unsteady, can emerge during treatment.

The mechanism runs through carbon dioxide. During stable sleep, breathing drive depends partly on keeping arterial CO₂ above an individual's apneic threshold. If ventilation rises enough to push CO₂ below that threshold, breathing effort can temporarily fall or stop, producing central hypopneas or apneas. As CO₂ climbs back, drive returns and can overshoot again. Those repeated swings create an unstable breathing pattern with recurring arousals. Some clinicians describe this as iatrogenic hyperventilation, a term that puts the problem where it belongs: in the treatment itself, which means it deserves a place in the risk-benefit conversation.

How common is this? Treatment-emergent central sleep apnea has been reported in roughly 8% of positive airway pressure titration studies conducted at lowland altitudes. Many cases resolve with continued treatment, but some persist and complicate the management of obstructive sleep apnea. Symptoms can include a sense of paradoxical breathlessness, anxiety and arousals, which is why it isn't just a line on a report.

Pressure delivery style matters here. Expiratory pressure relief comfort settings and bilevel therapy create a gap between inspiratory and expiratory pressure, which makes exhaling easier. That gap can augment ventilation and increase CO₂ elimination, and in some people that's exactly the therapeutic goal, such as in obesity hypoventilation or certain opioid-related central apneas. In people with high loop gain or a narrow CO₂ reserve, though, extra ventilation can increase central events instead.

A small but provocative 2025 study by Noah and colleagues looked at reducing inspiratory pressure in patients with this kind of treatment-emergent central sleep apnea. Among 13 evaluable patients, the central apnea index fell from 17.3 to 1.5 events per hour when inspiratory pressure was algorithmically set below expiratory pressure. The study wasn't built to establish a universal treatment strategy. Its value is in showing a principle: more ventilatory assistance isn't always the route to stable breathing. A separate study of Kairos positive airway pressure found obstructive sleep apnea control comparable to conventional CPAP, with less unintentional leak and better reported comfort. That doesn't establish that standard pressure-relief settings cause insomnia or central apnea, but it's a reminder to look at the pressure waveform rather than treating all positive airway pressure as physiologically identical.

Altitude adds another moving part. Thinner air stimulates ventilation, which lowers arterial CO₂ and can bring susceptible people closer to their apneic threshold. Pagel and colleagues examined patients treated with positive airway pressure at three elevations and found the proportion with a central apnea index above five events per hour rose from 10.6% at 4,660 feet to 38.7% at 7,100 feet. That's an observational study, so it can't prove cause, but the size of the difference is hard to wave away. For anyone living or traveling at elevation, it's a meaningful variable.

Breathing route matters too. Nasal and oronasal interfaces aren't interchangeable. Landry and colleagues reported that oronasal masks may increase upper airway collapsibility and the pressure needed to hold the airway open. Whether open-mouth breathing during recovery breaths contributes to ventilatory overshoot is still a hypothesis rather than an established mechanism, though it's a question clinicians in high-altitude practices raise often. The broader point is that pressure delivery, airway mechanics, mask type and altitude interact in ways a single summary number can't capture.

That's why reassuring device data don't close the case. A person can use therapy faithfully, see a good residual number on the screen, and still wake repeatedly. Device downloads are useful, but they don't measure sleep architecture or breathing control in full. When symptoms persist, a sleep team typically reviews pressure settings, pressure support, leak, breathing route, altitude and the possibility of treatment-emergent instability. If you use positive airway pressure and notice new breathlessness, anxiety or fragmented sleep, bring it to your sleep clinician rather than adjusting settings on your own.

When treatment appears linked to new physiological disturbance, the treatment belongs in the differential diagnosis.

Sedatives and the nervous system's long memory

Picture a patient who has taken lorazepam every night for twenty years. It may have started during a rough stretch of insomnia and became a fixture of the medication list, sitting alongside treatments for blood pressure or reflux. The nervous system that has absorbed two decades of regular benzodiazepine use isn't necessarily working the way it did before the first prescription.

Benzodiazepines boost inhibitory signaling through GABA-A receptors, making the brain's main calming neurotransmitter more effective. Z-drugs, a related class of sleep medications, act on overlapping receptor systems, though their pharmacology and clinical effects aren't identical. By enhancing that inhibition, these medications reduce neural excitability, ease anxiety and help people fall asleep.

The brain, however, adapts. Laboratory work on brain cells exposed to diazepam for prolonged periods has found reduced surface levels of certain GABA-A receptor subtypes and altered coupling between GABA and benzodiazepine binding sites. That's cell-level research, so it doesn't map neatly onto every patient, but it helps explain why tolerance and physiological dependence can develop during long-term treatment. It also offers a conceptual frame for why reducing a medication can bring back symptoms that weren't present before treatment began.

Here's where clinical judgment gets tricky. Imagine our twenty-year lorazepam user decides to cut back, perhaps because the drug no longer helps as much, or because of concerns about memory, falls or long-term safety. As the dose falls, sleep gets dramatically worse. There's longer wakefulness, heightened anxiety, restlessness and sensitivity to ordinary stimulation. The obvious reading is that the original insomnia has returned, maybe worse than before. From the patient's side, it can feel like confirmation that sleep without medication is impossible.

A more careful evaluation separates several phenomena. Recurrence means the original sleep disorder has come back. Rebound insomnia refers to a temporary worsening beyond pretreatment levels. Withdrawal is a broader physiological response to dose reduction or discontinuation, which can involve autonomic activation, anxiety, sensory disturbance and impaired sleep. These usually overlap, and untangling them in one person can be hard. But the distinction has consequences. If withdrawal-related hyperarousal is read only as proof of an irreversible insomnia disorder, the clinician may unintentionally reinforce the idea that ongoing sedation is the only option.

That's the core issue. The problem isn't only that the original treatment has lost effectiveness. The treatment may have produced a new physiological state that has to be assessed on its own terms, separate from the condition it was originally prescribed for.

Timing is part of this too. Drug elimination and neurological readjustment don't run on the same clock. Depending on the medication and its breakdown products, drug levels in the body can fall substantially over days, while the nervous system takes considerably longer to recalibrate. A 2025 joint clinical practice guideline on benzodiazepine tapering acknowledges that some people have withdrawal symptoms that outlast the expected drug clearance period and occasionally persist for months. That doesn't make prolonged withdrawal inevitable, and not every bad night after stopping is withdrawal. It does show that clearing a drug from the blood and restoring normal function are separate processes.

I've started calling this pattern borrowed sleep. After the drug has left the body, the nervous system is still rearranging the furniture, and the repayment can take time. That metaphor isn't meant to say hypnotic medications are inherently bad or inappropriate. Sedatives can provide real clinical benefit in selected situations. The concern is that sustained exposure adds another moving part to an already complicated picture, especially once physiological dependence has developed.

When dependence is present, abrupt discontinuation isn't a sensible strategy. Severe withdrawal, including seizures, can occur, and dose reduction should be individualized and medically supervised. The 2025 guideline describes gradual tapering, with slower schedules when clinically needed. A taper plan is a decision for the prescriber, and it shouldn't be improvised from an article.

Behavior matters as well. Someone who has relied on a medication for years may develop understandable anxiety about sleeping without it, and withdrawal-related sleeplessness can strengthen conditioned arousal, the learned association between bed and alertness. CBT-I can target those associations while providing support during a reduction. In a 2019 systematic review and meta-analysis, Takaesu and colleagues found that combining CBT-I with gradual benzodiazepine tapering improved short-term discontinuation outcomes compared with tapering alone. The advantage wasn't statistically significant at 12 months, so the picture is promising but not settled.

One distinction deserves emphasis. Physiological dependence isn't the same as addiction. It can develop in people who take a medication consistently and exactly as prescribed. Its presence doesn't, on its own, establish a substance use disorder. Patients dealing with these difficulties deserve an explanation rooted in physiology, not an implication of weak willpower or poor motivation. Their nervous system is adaptive, withdrawal-related hyperarousal can be real, and recovery often needs time, support and a carefully built plan.

The central clinical question is whether the hyperarousal we're seeing reflects the original disorder, a consequence of treatment, or some mix of both. Skip that question and we risk mistaking neuroadaptation for proof that the first diagnosis was right all along.

Three routes, one question

These three examples offer different routes to a similar presentation. Low iron in the brain may shift the chemical systems that govern the balance between sleep and wakefulness. Too much ventilatory support may destabilize breathing in a susceptible person and introduce new sleep-disrupting physiology. Long-term sedative exposure may leave adaptations that complicate sleep once the medication is reduced. The mechanisms differ, and so does the strength of evidence behind each. None should be assumed to explain a particular patient's symptoms without a proper clinical assessment.

Their shared lesson is that persistent wakefulness isn't one phenomenon, even when it arrives under the familiar label of hyperarousal or COMISA. Treating it as a single problem with a single cause is how useful clues get missed. That's also why the distinction between a question and a diagnosis matters in practice. It decides whether persistent wakefulness counts as something already explained or as a signal that more investigation may be warranted.

Looking ahead, the most useful research will be the kind that separates these pathways in individual patients: studies that link brain iron measures to sleep outcomes, trials that compare pressure waveforms in people with central events, and tapering studies that track which withdrawal features fade and which persist. Until those answers arrive, the practical habit is the same one McCarty keeps returning to. Keep asking what's driving the arousal, and check the drivers that are easy to miss.

Hyperarousal is a question, not a diagnosis. If you're living with a sleep problem that doesn't respond to the explanation you've been given, bring these possibilities to your sleep clinician, prescriber or pharmacist, and ask which ones have been ruled out.

Source: David McCarty · sleepreviewmag.com

From the same basket